维生素D与ω-3脂肪酸补充对年龄相关性黄斑变性风险的影响:VITAL随机临床试验辅助研究
结果显示,维生素D3组AMD事件风险比(HR)为1.02(95%CI 0.82-1.27),ω-3脂肪酸组HR为0.94(95%CI 0.76-1.17),均无显著影响。结论认为两种补充剂对AMD总体发病率或进展无显著作用。
要点
- 每日补充维生素D3或海洋ω-3脂肪酸未显著降低AMD总体事件风险。
- 维生素D3对AMD进展的HR为0.63(95%CI 0.33-1.21),无统计学意义。
- ω-3脂肪酸对AMD进展的HR为1.05(95%CI 0.56-1.97),无统计学意义。
核心结论
- 维生素D3或海洋ω-3脂肪酸补充对AMD的总体发病率或进展均无显著影响。
研究设计与样本
- 干预为每日维生素D3(胆钙化醇)2000 IU和海洋ω-3脂肪酸1克。
- 主要终点为总AMD事件,包括新发AMD和基线AMD患者进展为晚期AMD,基于自我报告并经医疗记录核实。
- 分析采用意向性治疗人群。
主要发现
- 中位治疗和随访5.3年(范围3.8-6.1年)期间,324名参与者发生AMD事件(285例新发AMD和39例进展为晚期AMD)。
- 维生素D3组发生163例事件,安慰剂组161例(HR 1.02;95%CI 0.82-1.27)。
- ω-3脂肪酸组发生157例事件,安慰剂组167例(HR 0.94;95%CI 0.76-1.17)。
- 维生素D3对新发AMD的HR为1.09(95%CI 0.86-1.37),对AMD进展的HR为0.63(95%CI 0.33-1.21)。
- ω-3脂肪酸对新发AMD的HR为0.93(95%CI 0.73-1.17),对AMD进展的HR为1.05(95%CI 0.56-1.97)。
关键数值与推荐
- 主要终点总AMD事件的维生素D3组HR 1.02(95%CI 0.82-1.27),ω-3脂肪酸组HR 0.94(95%CI 0.76-1.17)。
临床怎么用
- 基于本随机试验结果,不应以预防AMD为目的常规推荐每日补充维生素D3 2000 IU或海洋ω-3脂肪酸1克。
- 对于已患AMD者,补充维生素D3或ω-3脂肪酸未显示显著延缓进展至晚期AMD的作用。
局限性
- 原文未报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Observational studies suggest that higher intake or blood levels of vitamin D and marine ω-3 fatty acids may be associated with lower risks of age-related macular degeneration (AMD). However, evidence from randomized trials is limited. OBJECTIVE: To evaluate whether daily supplementation with vitamin D3, marine ω-3 fatty acids, or both prevents the development or progression of AMD. DESIGN, SETTING, AND PARTICIPANTS: This was a prespecified ancillary study of the Vitamin D and Omega-3 Trial (VITAL), a nationwide, placebo-controlled, 2 × 2 factorial design randomized clinical trial of supplementation with vitamin D and marine ω-3 fatty acids for the primary prevention of cancer and cardiovascular disease. Participants included 25 871 men and women in the US. Randomization was from November 2011 to March 2014, and study pill-taking ended as planned on December 31, 2017. INTERVENTIONS: Vitamin D3 (cholecalciferol), 2000 IU per day, and marine ω-3 fatty acids, 1 g per day. MAIN OUTCOMES AND MEASURES: The primary end point was total AMD events, a composite of incident cases of AMD plus cases of progression to advanced AMD among participants with AMD at baseline, based on self-report confirmed by medical record review. Analyses were conducted using the intention-to-treat population. RESULTS: In total, 25 871 participants with a mean (SD) age of 67.1 (7.0) years were included in the trial. Of them, 50.6% were women, 71.3% were self-declared non-Hispanic White participants, and 20.2% were Black participants. During a median (range) of 5.3 (3.8-6.1) years of treatment and follow-up, 324 participants experienced an AMD event (285 incident AMD and 39 progression to advanced AMD). For vitamin D3, there were 163 events in the treated group and 161 in the placebo group (hazard ratio [HR], 1.02; 95% CI, 0.82-1.27). For ω-3 fatty acids, there were 157 events in the treated group and 167 in the placebo group (HR, 0.94; 95% CI, 0.76-1.17). In analyses of individual components for the primary end point, HRs comparing vitamin D3 groups were 1.09 (95% CI, 0.86-1.37) for incident AMD and 0.63 (95% CI, 0.33-1.21) for AMD progression. For ω-3 fatty acids, HRs were 0.93 (95% CI, 0.73-1.17) for incident AMD and 1.05 (95% CI, 0.56-1.97) for AMD progression. CONCLUSION AND RELEVANCE: Neither vitamin D3 nor marine ω-3 fatty acid supplementation had a significant overall effect on AMD incidence or progression. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01782352.
引用
- Christen WG, Cook NR, Manson JE, et al. Effect of Vitamin D and ω-3 Fatty Acid Supplementation on Risk of Age-Related Macular Degeneration: An Ancillary Study of the VITAL Randomized Clinical Trial. JAMA Ophthalmol. 2020. PMID: 33119047. doi:10.1001/jamaophthalmol.2020.4409
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。